Titan Pharmaceuticals Inc

Titan Pharmaceuticals — Investor Presentation (September 2014)

20 slides from Titan Pharmaceuticals's investor presentation, Sep 10, 2014

  1. Slide 1: Corporate Presentation

    Corporate Presentation Sunil Bhonsle Sept. 2014

  2. Slide 2: Safe Harbor

    Safe Harbor The presentation may contain “forward - looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Reference is made in particular to the description of our plans and objectives for future operations, assump

  3. Slide 3: Company Overview

    Company Overview Titan Pharmaceuticals specializes in the development of treatments for select chronic diseases utilizing its proprietary ProNeura ™ technology platform • ProNeura : Proprietary Long - Term Drug Delivery Platform ▫ Provides non - fluctuating medication levels over periods of six mont

  4. Slide 4: Probuphine: The First of its Kind

    Probuphine: The First of its Kind Expected to be the first long - acting buprenorphine product on the market for the treatment of opioid dependence • Six month sustained release of buprenorphine • Peak sales potential: $300 - $500 million • U.S. and Canadian partnership with Braeburn Pharmaceuticals

  5. Slide 5: The Epidemic of Opioid Dependence

    The Epidemic of Opioid Dependence • Increasingly recognized as a global epidemic by world health authorities • Addiction - a primary, chronic disease of brain reward, motivation, memory and neurobiological circuitry ▫ Cravings, accompanied by lack of impulse control ▫ Abstinence is rarely a successf

  6. Slide 6: Opioid Dependence: Treatment Overview

    Opioid Dependence: Treatment Overview Buprenorphine is the Gold Standard in the U.S., Replacing Methadone • Buprenorphine pharmacology makes it an effective, safer and more convenient treatment option ▫ Controls withdrawal symptoms and cravings without inducing opioid euphoria in patients ▫ Convenie

  7. Slide 7: Treatment of Opioid Dependence: Expanding the Market

    Sources: IMS Health Treatment of Opioid Dependence: Expanding the Market • Daily buprenorphine dominates the current market ▫ U.S. sales of daily oral formulations of buprenorphine ( Suboxone ® ) exceeded $1.4B in 2012 ▫ U.S. buprenorphine prescriptions have exceeded those of methadone since 2006 •

  8. Slide 8: Proprietary ProNeura Technology: Probuphine Implant

    EVA polymer Buprenorphine Blended & Extruded Probuphine Proprietary ProNeura Technology: Probuphine Implant • Implant contains 80 mg of buprenorphine HCl , uniformly distributed throughout the ethylene vinyl acetate co - polymer (EVA) matrix • No reservoir, therefore no risk of drug dumping • Follow

  9. Slide 9: Probuphine Clinical Summary

    Probuphine Clinical Summary • Six clinical studies completed to date with final Phase 3 study under way ▫ Initial small dose finding study ▫ Two well - controlled Phase 3 safety and efficacy studies showing clinical and statistical superiority over placebo and non - inferiority to Suboxone published

  10. Slide 10: Phase 3 Clinical Study in Progress (Pro-814)

    Phase 3 Clinical Study in Progress (Pro - 814) The clinical study is a randomized, double blind and double dummy design that will provide information for a non - inferiority comparison of a six - month treatment with a dose of four Probuphine implants to treatment with 8 mg or less of an approved da

  11. Slide 11: Probuphine Value Proposition

    Probuphine Value Proposition Probuphine is the first and only potential treatment for opioid dependence that provides non - fluctuating blood levels of buprenorphine around - the - clock for a period of six months 11 Titan Pharmaceuticals Company Overview | Proprietary & Confidential | ©2014 Titan P

  12. Slide 12: Titan: Adding Value Beyond Probuphine

    Titan: Adding Value Beyond Probuphine Proprietary ProNeura Technology Platform • Long - term drug delivery technology validated through the Probuphine program • Potential for the treatment of select chronic diseases for which low dose long - term delivery and stable drug levels may offer advantages

  13. Slide 13: Parkinson's Disease Overview

    Definition Characterized by the loss of dopaminergic neurons which alters activity in the brain region impacting movement and motor function Treatment Treated with drugs designed to replace or mimic dopamine in the brain Following several years of chronic treatment, these drugs lose their benefit an

  14. Slide 14: Treated Population Increasing Worldwide

    Treated Population Increasing Worldwide 14 Based on information from Titan and other sources believed to be reliable and prepared exclusively for Titan. Woodside Capita l P artners is not responsible for any use that Titan may make of this material.

  15. Slide 15: Therapeutics Market

    Therapeutics Market • About 1.5 million people in the U.S. have Parkinson’s disease according to the Parkinson’s Disease Foundation. The number is expected to double by 2030 because of the aging population. 15 Titan Pharmaceuticals Company Overview | Proprietary & Confidential | ©2014 Titan Pharmace

  16. Slide 16: ProNeura Parkinson's Disease Program: Non-clinical Proof of Concept

    ProNeura Parkinson’s Disease Program Non - clinical Proof of Concept • Ropinirole ( Requip ® ), a generic dopamine agonist marketed by GSK for PD, was evaluated in a Parkinsonian primate model using ProNeura technology • Results demonstrated: ▫ Sustained plasma ropinirole levels for several months f

  17. Slide 17: ProNeura Parkinson's Disease Program: Next Steps

    ProNeura Parkinson’s Disease Program Next Steps • Optimize implant formulation of ropinirole ; develop non - clinical study plan to support Investigational New Drug (IND) application • Design proof of concept clinical study with assistance of a Scientific Advisory Board • Conduct a pre - IND meeting

  18. Slide 18: Titan Pharmaceuticals Summary

    Titan Pharmaceuticals Summary • Titan Pharmaceuticals specializes in the development of treatments for select chronic diseases, utilizing its innovative ProNeura technology platform • Probuphine , a long - acting controlled - release buprenorphine product for opioid dependence; expected completion o

  19. Slide 19: Titan Executive Management

    • Marc Rubin, M.D, Executive Chairman and Director ▫ Seven years with Titan Pharmaceuticals. Former Head of Global Research & Development and member of the Board of Management at Bayer Pharma. Executive R&D and commercial responsibilities at GSK for 13 years. Twenty - four years in the pharmaceutica

  20. Slide 20: Thank You

    Thank You Sunil Bhonsle Sept. 2014

Titan Pharmaceuticals — Investor Presentation (September 2014) on 6ix